BCDA
BioCardia, Inc.
Next earnings Aug 10, 2026 · consensus $-0.18 EPS
$1.20
▲ +10.09%$1.20▼ -42.31%
over 1Y
L $0.80EODHDH $2.42
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+10.1%
1W+24.1%
1M+33.3%
3M+3.4%
YTD-5.5%
1Y-42.3%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Revenue fell -100.0% YoY.
BioCardia, Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -919.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.01M | $1.35M | $477K | $58.0K | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.6M | -$11.9M | -$11.6M | -$8.00M | -$8.28M |
| Net income | -$12.6M | -$11.9M | -$11.6M | -$7.95M | -$8.23M |
| Diluted EPS | -$0.75 | — | — | — | — |
| Net margin | -1243.6% | -880.7% | -2425.8% | -13700.0% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$10.6M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-62.7%
FCF yield-56.7%
Quality & risk
ROIC (est.)-730.7%
Free cash flow-$7.44M
Total debt—
Net cash$2.50M
Altman Z-Score-73.83 distress
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+133.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-06-12). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-172026-06-22open ↗8-KPeriod ending 2026-06-182026-06-18open ↗8-KPeriod ending 2026-06-122026-06-12open ↗4Period ending 2026-06-092026-06-09open ↗8-KPeriod ending 2026-06-082026-06-08open ↗8-KPeriod ending 2026-06-052026-06-05open ↗8-KPeriod ending 2026-05-282026-05-28open ↗4Period ending 2026-05-192026-05-21open ↗8-KPeriod ending 2026-05-212026-05-21open ↗4Period ending 2026-05-182026-05-18open ↗4Period ending 2026-05-152026-05-15open ↗
Frequently asked
- Is BioCardia, Inc. (BCDA) a buy?
- BCDA currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Revenue fell -100.0% YoY.
- What is BioCardia, Inc.'s quality score?
- BCDA scores 33.35897435897436/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000925741, latest 10-Q filed 2026-05-15) · EODHD · as of 6/26/2026, 5:53:31 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.